Literature DB >> 31187211

Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs.

Hannah Petrek1, Neelu Batra1, Pui Yan Ho1, Mei-Juan Tu1, Ai-Ming Yu2.   

Abstract

Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small interfering RNAs (siRNAs), and long noncoding RNAs (lncRNAs), regulate target gene expression and can be used as tools for understanding biological processes and identifying new therapeutic targets. Currently, ncRNA molecules for research and therapeutic use are limited to ncRNA mimics made by chemical synthesis. We have recently established a high-yield and cost-effective method of producing bioengineered or biologic ncRNA agents (BERAs) through bacterial fermentation, which is based on a stable tRNA/pre-miR-34a carrier (~ 180 nt) that accommodates target small RNAs. Nevertheless, it remains a challenge to heterogeneously express longer ncRNAs (e.g., > 260 nt), and it is unknown if single BERA may carry multiple small RNAs. To address this issue, we hypothesized that an additional human pre-miR-34a could be attached to the tRNA/pre-miR-34a scaffold to offer a new tRNA/pre-miR-34a/pre-miR-34a carrier (~ 296 nt) for the accommodation of multiple small RNAs. We thus designed ten different combinatorial BERAs (CO-BERAs) that include different combinations of miRNAs, siRNAs, and antagomirs. Our data showed that all target CO-BERAs were successfully expressed in Escherichia coli at high levels, greater than 40% in total bacterial RNAs. Furthermore, recombinant CO-BERAs were purified to a high degree of homogeneity by fast protein liquid chromatography methods. In addition, CO-BERAs exhibited strong anti-proliferative activities against a variety of human non-small cell lung cancer cell lines. These results support the production of long ncRNA molecules carrying different warhead small RNAs for multi-targeting which may open avenues for developing new biologic RNAs as experimental, diagnostic, and therapeutic tools.

Entities:  

Keywords:  Bioengineering; Lung cancer; Noncoding RNA; microRNA; siRNA

Mesh:

Substances:

Year:  2019        PMID: 31187211      PMCID: PMC7068804          DOI: 10.1007/s00253-019-09934-5

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  48 in total

1.  Fluorescence imaging of cellular metabolites with RNA.

Authors:  Jeremy S Paige; Thinh Nguyen-Duc; Wenjiao Song; Samie R Jaffrey
Journal:  Science       Date:  2012-03-09       Impact factor: 47.728

2.  A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold.

Authors:  Luc Ponchon; Geneviève Beauvais; Sylvie Nonin-Lecomte; Frédéric Dardel
Journal:  Nat Protoc       Date:  2009-05-28       Impact factor: 13.491

3.  Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.

Authors:  T Yamadori; Y Ishii; S Homma; Y Morishima; K Kurishima; K Itoh; M Yamamoto; Y Minami; M Noguchi; N Hizawa
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

4.  New insights for therapeutic recombinant human miRNAs heterologous production: Rhodovolum sulfidophilum vs Escherichia coli.

Authors:  Patrícia Pereira; Augusto Q Pedro; João A Queiroz; Ana R Figueiras; Fani Sousa
Journal:  Bioengineered       Date:  2017-03-10       Impact factor: 3.269

5.  Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells.

Authors:  Mei-Mei Li; Wei-Peng Wang; Wen-Juan Wu; Min Huang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2014-08-26       Impact factor: 3.922

Review 6.  Bioengineering of noncoding RNAs for research agents and therapeutics.

Authors:  Pui Yan Ho; Ai-Ming Yu
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-01-13       Impact factor: 9.957

7.  Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer.

Authors:  Liron Bar-Peled; Esther K Kemper; Radu M Suciu; Ekaterina V Vinogradova; Keriann M Backus; Benjamin D Horning; Thomas A Paul; Taka-Aki Ichu; Robert U Svensson; Jose Olucha; Max W Chang; Bernard P Kok; Zhou Zhu; Nathan T Ihle; Melissa M Dix; Ping Jiang; Matthew M Hayward; Enrique Saez; Reuben J Shaw; Benjamin F Cravatt
Journal:  Cell       Date:  2017-09-28       Impact factor: 41.582

8.  A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications.

Authors:  Qiu-Xia Chen; Wei-Peng Wang; Su Zeng; Shiro Urayama; Ai-Ming Yu
Journal:  Nucleic Acids Res       Date:  2015-03-23       Impact factor: 16.971

9.  Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.

Authors:  Chao Jian; Mei-Juan Tu; Pui Yan Ho; Zhijian Duan; Qianyu Zhang; Jing-Xin Qiu; Ralph W DeVere White; Theodore Wun; Primo N Lara; Kit S Lam; Ai-Xi Yu; Ai-Ming Yu
Journal:  Oncotarget       Date:  2017-05-09

10.  Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity.

Authors:  Joseph L Jilek; Qian-Yu Zhang; Mei-Juan Tu; Pui Yan Ho; Zhijian Duan; Jing-Xin Qiu; Ai-Ming Yu
Journal:  Mol Ther Nucleic Acids       Date:  2019-01-24
View more
  10 in total

1.  Bioengineered RNA Therapy in Patient-Derived Organoids and Xenograft Mouse Models.

Authors:  Mei-Juan Tu; Colleen M Yi; Gavin M Traber; Ai-Ming Yu
Journal:  Methods Mol Biol       Date:  2022

2.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

3.  Expression and Purification of tRNA/ pre-miRNA-Based Recombinant Noncoding RNAs.

Authors:  Mei-Juan Tu; Halley K Wright; Neelu Batra; Ai-Ming Yu
Journal:  Methods Mol Biol       Date:  2021

4.  Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth.

Authors:  Hannah Petrek; Pui Yan Ho; Neelu Batra; Mei-Juan Tu; Qianyu Zhang; Jing-Xin Qiu; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2021-01-03       Impact factor: 6.100

5.  The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug.

Authors:  Dai-Feng Li; Ying Yuan; Mei-Juan Tu; Xiang Hu; Yi-Zhou Li; Wan-Rong Yi; Peng-Cheng Li; Yong Zhao; Zhen Cheng; Ai-Ming Yu; Chao Jian; Ai-Xi Yu
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

Review 6.  ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery.

Authors:  Miguel Hueso; Adrián Mallén; Marc Suñé-Pou; Josep M Aran; Josep M Suñé-Negre; Estanislao Navarro
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

7.  miR-34a-5p inhibits the malignant progression of KSHV-infected SH-SY5Y cells by targeting c-fos.

Authors:  Shuyuan Wu; Zhaofu Wu; Huiling Xu; Jinli Zhang; Wenyi Gu; Xiaohua Tan; Zemin Pan; Dongdong Cao; Dongmei Li; Lei Yang; Dongmei Li; Yuanming Pan
Journal:  PeerJ       Date:  2022-04-15       Impact factor: 3.061

Review 8.  Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination.

Authors:  Ai-Ming Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2021-08-14       Impact factor: 13.400

Review 9.  Novel approaches for efficient  in vivo fermentation production of noncoding RNAs.

Authors:  Ai-Ming Yu; Neelu Batra; Mei-Juan Tu; Colleen Sweeney
Journal:  Appl Microbiol Biotechnol       Date:  2020-01-17       Impact factor: 4.813

Review 10.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.